Hudson Bay Capital Management
OBIO icon

Hudson Bay Capital Management’s Orchestra BioMed OBIO Stock Holding History

Hudson Bay Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$302K Buy
71,134
+21,709
+44% +$92.4K ﹤0.01% 1031
2025
Q4 		$205K Buy
+49,425
New +$199K ﹤0.01% 967
2022
Q3 		– Sell
-275,298
Closed -$2.74M – 1313
2022
Q2 		$2.74M Buy
+275,298
New +$2.74M 0.02% 688

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Hudson Bay Capital Management's OBIO Position: Q1 2026 in Review

Hudson Bay Capital Management increased its Orchestra BioMed (OBIO) stake by 44% in Q1 2026, buying an estimated $92.4K and bringing the position to 71,134 shares worth $302K. The position accounts for ﹤0.01% of the portfolio, ranked #1031.

Hudson Bay Capital Management first reported a position in OBIO in Q2 2022 and has held it in 3 quarters since. The position peaked at $2.74M in Q2 2022. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • Hudson Bay Capital Management held 71,134 shares of Orchestra BioMed worth $302K as of Q1 2026.
  • Hudson Bay Capital Management bought 21,709 Orchestra BioMed shares in Q1 2026, an estimated $92.4K.
  • Orchestra BioMed made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #1031 holding.
  • Hudson Bay Capital Management first reported a position in Orchestra BioMed in Q2 2022 and has held it in 3 quarters since.
  • Hudson Bay Capital Management's Orchestra BioMed position peaked at $2.74M in Q2 2022.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.